Chemotherapy-induced neuropathiesa growing problem for patients and health care providers

被引:135
作者
Banach, Marta [1 ]
Juranek, Judyta K. [2 ,3 ]
Zygulska, Aneta L. [4 ]
机构
[1] Jagiellonian Univ, Coll Med, Dept Neurol, Krakow, Poland
[2] NYU, Dept Med, Langone Med Ctr, 550 1St Ave, New York, NY 10016 USA
[3] Univ Warmia & Mazury, Fac Med Sci, Dept Pathol, Olsztyn, Poland
[4] Jagiellonian Univ, Univ Hosp, Dept Oncol, Krakow, Poland
来源
BRAIN AND BEHAVIOR | 2017年 / 7卷 / 01期
关键词
chemotherapy-induced neuropathies; drug neurotoxicity; neuropathy risk factors; INDUCED PERIPHERAL NEUROPATHY; PLACEBO-CONTROLLED TRIAL; OXALIPLATIN-INDUCED NEUROPATHY; SMALL FIBER NEUROPATHY; QUALITY-OF-LIFE; DOUBLE-BLIND; MULTIPLE-MYELOMA; CANCER-PATIENTS; COLORECTAL-CANCER; OVARIAN-CANCER;
D O I
10.1002/brb3.558
中图分类号
B84 [心理学]; C [社会科学总论]; Q98 [人类学];
学科分类号
03 ; 0303 ; 030303 ; 04 ; 0402 ;
摘要
IntroductionChemotherapy-induced neuropathies are one of the most common side effects of cancer treatment, surpassing bone marrow suppression and kidney dysfunction. Chemotherapy effects on the nervous system vary between different classes of drugs and depend on specific chemical and physical properties of the drug used. The three most neurotoxic classes of anti-cancer drugs are: platinum-based drugs, taxanes, and thalidomide and its analogs; other, less neurotoxic but also commonly used drugs are: bortezomib, ixabepilone, and vinca alkaloids. MethodsHere, in this paper, based on our experience and current knowledge, we provide a short review of the most common, neuropathy-inducing anti-cancer drugs, describe the most prevalent neuropathy symptoms produced by each of them, and outline preventive measures and treatment guidelines for cancer patients suffering from neuropathy and for their health care providers. ResultsPatients should be encouraged to report any signs of neuropathic pain, alteration in sensory perception, tingling, numbness, burning, increased hot/cold sensitivity and motor dysfunctions as early as possible. If known neurotoxic chemotherapeutics are used, a neurological examination with electrophysiological evaluation should be implemented early in the course of treatment so, both patients and physicians would be better prepared to cope with possible neurotoxic effects. ConclusionsThe use of neurotoxic chemotherapeutics should be closely monitored and if clinically permitted, that is, if a patient shows signs of cancer regression, drug doses should be reduced or combined with other less neurotoxic anti-cancer medication. If not counteractive, the use of over the counter antineuropathic supplements such as calcium or magnesium might be encouraged. If physically possible, patients should also be encouraged to exercise regularly and avoid factors that might increase nerve damage such as excessive drinking, smoking, or sitting in a cramped position.
引用
收藏
页数:8
相关论文
共 75 条
[1]   Taxanes: Microtubule and Centrosome Targets, and Cell Cycle Dependent Mechanisms of Action [J].
Abal, M. ;
Andreu, J. M. ;
Barasoain, I. .
CURRENT CANCER DRUG TARGETS, 2003, 3 (03) :193-203
[2]  
[Anonymous], EVID BASED COMPLEMEN
[3]  
[Anonymous], 2014, Global status report on noncommunicable diseases 2014, P1
[4]   Whole-Exome Sequencing Reveals Defective CYP3A4 Variants Predictive of Paclitaxel Dose-Limiting Neuropathy [J].
Apellaniz-Ruiz, Maria ;
Lee, Mi-Young ;
Sanchez-Barroso, Laras ;
Gutierrez-Gutierrez, Gerardo ;
Calvo, Isabel ;
Garcia-Estevez, Laura ;
Sereno, Maria ;
Garcia-Donas, Jesus ;
Castelo, Beatriz ;
Guerra, Eva ;
Leandro-Garcia, Luis J. ;
Cascon, Alberto ;
Johansson, Inger ;
Robledo, Mercedes ;
Ingelman-Sundberg, Magnus ;
Rodriguez-Antona, Cristina .
CLINICAL CANCER RESEARCH, 2015, 21 (02) :322-328
[5]   Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature [J].
Argyriou, Andreas A. ;
Iconomou, Gregoris ;
Kalofonos, Haralabos P. .
BLOOD, 2008, 112 (05) :1593-1599
[6]   A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results [J].
Argyriou, Andreas A. ;
Chroni, Elisabeth ;
Koutras, Angelos ;
Iconomou, Gregoris ;
Papapetropoulos, Spiridon ;
Polychronopoulos, Panagiotis ;
Kalofonos, Haralabos P. .
SUPPORTIVE CARE IN CANCER, 2006, 14 (11) :1134-1140
[7]   Clinical pattern and associations of oxaliplatin acute neurotoxicity [J].
Argyriou, Andreas A. ;
Cavaletti, Guido ;
Briani, Chiara ;
Velasco, Roser ;
Bruna, Jordi ;
Campagnolo, Marta ;
Alberti, Paola ;
Bergamo, Francesca ;
Cortinovis, Diego ;
Cazzaniga, Marina ;
Santos, Cristina ;
Papadimitriou, Konstantinos ;
Kalofonos, Haralabos P. .
CANCER, 2013, 119 (02) :438-444
[8]   Platinum-Induced Neurotoxicity and Preventive Strategies: Past, Present, and Future [J].
Avan, Abolfazl ;
Postma, Tjeerd J. ;
Ceresa, Cecilia ;
Avan, Amir ;
Cavaletti, Guido ;
Giovannetti, Elisa ;
Peters, Godefridus J. .
ONCOLOGIST, 2015, 20 (04) :411-432
[9]   Chemotherapy-induced neuropathiesa growing problem for patients and health care providers [J].
Banach, Marta ;
Juranek, Judyta K. ;
Zygulska, Aneta L. .
BRAIN AND BEHAVIOR, 2017, 7 (01)
[10]   UTILITY OF SKIN BIOPSY IN MANAGEMENT OF SMALL FIBER NEUROPATHY [J].
Boruchow, Scott A. ;
Gibbons, Christopher H. .
MUSCLE & NERVE, 2013, 48 (06) :877-882